Nureca Ltd. (NURECA) AI Stock Analysis

• Market Cap: ₹2.34B
• Dividend Yield: N/A
• Average Volume (3M): 2.79K
• Price to Earnings (P/E): 341.4
• Beta (1Y): 0.77
• Revenue Growth: 35.84%
• EPS Growth: -100.52%
• Country: IN
• Employees: 138
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Devices
• EPS (TTM): 0.81
• Shares Outstanding: 10,000,175
• 10 Day Avg. Volume: 1,543
• 30 Day Avg. Volume: 2,788
• PEG Ratio: -1.76
• Price to Book (P/B): 1.13
• Price to Sales (P/S): 2.00
• P/FCF Ratio: -9.36
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹254.00
• Price Target Upside: 8.59% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: ₹254.00 ▲(8.59% Upside)

Nureca Ltd.'s stock is primarily weighed down by negative profitability and valuation concerns. Despite strong equity, the company needs to address revenue declines and cash flow inefficiencies. The technical indicators suggest potential for recovery, but the overall outlook remains cautious.

Nureca Ltd. Business Overview & Revenue Model

Company Description

Nureca Ltd. (NURECA) is a company operating in the healthcare and wellness sector, focusing on providing a wide range of products that enhance health and well-being. The company is known for its offerings in categories such as chronic disease management, lifestyle products, and healthcare devices. Nureca's core product lineup includes devices like blood pressure monitors, thermometers, nebulizers, and other diagnostic and monitoring equipment aimed at both consumer and professional segments.

How the Company Makes Money

Nureca Ltd. generates revenue primarily through the sale of its healthcare and wellness products. Its revenue streams are diversified across multiple product categories, including chronic disease management devices, lifestyle products, and healthcare monitoring equipment. The company sells these products through various distribution channels, including online platforms and retail networks, which helps in reaching a broad customer base. Strategic partnerships with e-commerce platforms enhance its market penetration and sales reach, contributing significantly to its earnings. Additionally, Nureca may engage in partnerships with healthcare providers or institutions to expand its market presence and drive sales.

Nureca Ltd. Financial Statement Overview

Summary

Nureca Ltd. shows strong equity and prudent debt management, but faces challenges with declining revenues, negative profitability, and cash flow inefficiencies. Improvements in operational efficiency and cash management are needed.

Income Statement

Nureca Ltd. has shown volatile revenue trends with a decline in revenue from 2022 to 2025. The gross profit margin remains moderate at approximately 38% in 2025, but net profitability is a concern with fluctuating net income, swinging to losses in recent periods. The EBIT margin is negative, indicating operational challenges. EBITDA shows improvement in 2025 compared to previous years, but overall performance remains inconsistent.

Balance Sheet

Nureca Ltd.'s balance sheet showcases strong equity with a high equity ratio of around 92% in 2025, indicating low leverage. The debt-to-equity ratio is favorable, suggesting prudent debt management. However, declining total assets over recent periods may signal underlying issues in asset management or utilization.

Cash Flow

The cash flow analysis reveals a challenging financial position with negative free cash flow growth and operating cash flow. The free cash flow to net income ratio is unfavorable, highlighting inefficiencies in converting income to cash. Despite some capital investment, liquidity remains a concern.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.10B	1.10B	919.28M	1.11B	2.56B	2.13B
Gross Profit	331.80M	231.33M	311.42M	355.94M	1.23B	1.14B
EBITDA	48.95M	48.95M	2.41M	-79.04M	632.04M	636.83M
Net Income	8.46M	8.46M	-17.94M	-82.50M	449.60M	463.74M
Balance Sheet
Total Assets	2.10B	2.10B	2.05B	2.07B	2.19B	1.86B
Cash, Cash Equivalents and Short-Term Investments	736.29M	1.30B	1.14B	1.02B	927.10M	1.27B
Total Debt	49.66M	49.66M	25.16M	33.27M	44.05M	38.85M
Total Liabilities	156.91M	156.91M	120.54M	116.97M	159.32M	226.54M
Stockholders Equity	1.94B	1.94B	1.93B	1.95B	2.03B	1.63B
Cash Flow
Free Cash Flow	0.00	-234.06M	-37.98M	98.31M	-46.00M	341.40M
Operating Cash Flow	0.00	-190.83M	-27.12M	102.27M	13.99M	348.67M
Investing Cash Flow	0.00	84.39M	175.76M	-164.56M	-30.89M	-1.10B
Financing Cash Flow	0.00	-1.69M	-13.03M	-15.07M	-73.02M	923.39M

Nureca Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 233.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NURECA, the sentiment is Negative. The current price of 233.9 is below the 20-day moving average (MA) of 244.28, below the 50-day MA of 267.20, and below the 200-day MA of 270.61, indicating a bearish trend. The MACD of -9.37 indicates Positive momentum. The RSI at 36.23 is Neutral, neither overbought nor oversold. The STOCH value of 15.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NURECA.

Nureca Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADVENZYMES	68 Neutral	₹34.34B	25.08		1.71%	5.89%	-1.30%
MOREPENLAB	65 Neutral	₹25.43B	27.24		―	2.12%	-25.99%
ZOTA	54 Neutral	₹41.50B	―		0.07%	71.72%	-125.44%
SOLARA	53 Neutral	₹28.75B	124.47		―	-7.29%	―
Sector *	51 Neutral	$7.46B	-0.16	-46.00%	2.25%	22.82%	-2.28%
INDOCO	47 Neutral	₹26.29B	96.22		0.52%	-8.28%	-247.34%
NURECA	45 Neutral	₹2.34B	341.37		―	35.84%	-100.52%